DIACCURATE acquires BIOKINESIS to create a sole-in-class biotech player in oncology and ...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. DIACCURATE acquires BIOKINESIS to create a sole-in-class biotech player in oncology and ... DIACCURATEJanuary 12, 2021 GMT Dr. Dominique BRIDON leads the new entity DIACCURATE is now developing 3 programs in cancer and immunotherapy DIACCURATE will be initiating a first clinical trial by early 2022 Paris, France, January 12, 2021 By acquiring BIOKINESIS, a French biotech that develops the very first anticancer compound targeting the Golgi apparatus, DIACCURATE comforts its “sole-in-class” ther...
Source: apnews.com